GlassScriptPhysician profile
Barbara Cartabuke-Mule
NPI 1962492389
$12,454.07
in general payments reported to CMS, 2019-2025
44 companies · $2,965 in 2025
The $2,965 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,929 · 2022: $2,010 · 2023: $2,684 · 2024: $2,866 · 2025: $2,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,515.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,205.05 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $780.72 | 2022-2025 | |
| Novo Nordisk INC | $753.76 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $717.52 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $659.65 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $594.52 | 2021-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $580.00 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $573.04 | 2023-2025 | |
| Dexcom, INC. | $561.42 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $521.82 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $474.74 | 2022-2025 | |
| Medtronic, INC. | $454.33 | 2021-2025 | Minimed 780g |
| Intuity Medical INC | $410.42 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Cequr Corporation | $360.09 | 2023-2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $352.65 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $333.70 | 2021-2025 | Repatha, Evenity, Repatha |
| Mannkind Corporation | $319.57 | 2021-2023 | V-Go |
| Tandem Diabetes Care, INC. | $295.26 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $294.57 | 2021-2023 | Korlym |
| Radius Health, INC. | $292.37 | 2021-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $254.84 | 2021-2025 | Unithroid |
| Ibsa Pharma INC. | $242.37 | 2024-2025 | Tirosint, Licart, Flector |
| Recordati_rare_diseases_inc. | $165.95 | 2025 | Isturisa |
| Amphastar Pharmaceuticals, INC. | $162.56 | 2023-2025 | Baqsimi |
| Kowa Pharmaceuticals America, INC. | $136.72 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $122.51 | 2024-2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $118.33 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $117.17 | 2025 | Strensiq |
| Madrigal Pharmaceuticals | $75.90 | 2025 | Rezdiffra |
| Avvisto Therapeutics, LLC | $70.91 | 2024 | Cycloset |
| Ipsen Biopharmaceuticals, INC | $68.45 | 2022-2023 | Somatuline Depot |
| Ascensia Diabetes Care US INC. | $64.01 | 2025 | |
| Averitas Pharma INC. | $48.88 | 2024-2025 | Qutenza |
| Pfizer INC. | $45.38 | 2023 | |
| Merck Sharp & Dohme LLC | $36.76 | 2021 | |
| Beta Bionics, INC. | $25.57 | 2024 | Ilet Bionic Pancreas |
| Becton, Dickinson and Company | $25.38 | 2022 | |
| Halozyme INC | $22.62 | 2023 | |
| Amryt Pharma Holdings LTD | $22.43 | 2022 | |
| Clarus Therapeutics INC. | $20.00 | 2021 | |
| Chiesi USA, INC. | $19.33 | 2024 | Mycapssa |
| Nevro Corp. | $19.15 | 2022 | |
| Currax Pharmaceuticals LLC | $17.68 | 2022 | |
| Lifescan, INC. | $15.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Cartabuke-Mule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.